MedTrace Logo

Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

NCT05842707 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-05-06

No results posted yet for this study

Summary

To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.

Conditions

  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

dualCAR-NK19/70 cell

Given by IV (vein)

Sponsors & Collaborators

  • Aibin Liang，MD，Ph.D.

    lead OTHER

Principal Investigators

  • aibin Liang · Shanghai Tongji Hospital, Tongji University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-18
Primary Completion
2028-01-18
Completion
2029-01-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05842707 on ClinicalTrials.gov